Customer No. 09629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, NW
Washington, D.C. 20004
(202) 739-3000

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claim 1 has been amended as follows:

1. (Amended) A method of selectively targeting a composition **to an activated vascular site**, **comprising administering to the activated vascular site, a composition** selected from the group **consisting** of: (a) particles, excluding liposomes, having a zeta potential in the range of about +25 mV to +100 mV in about 0.05 mM KCl solution at about pH 7.5; (b) molecules having an isoelectric point above 7.5; (c) liposomes containing cationic lipids in the range of about 25 mol% to 50 mol%; (d) magnetosomes with a cationic lipid layer having a zeta potential in the range of about +25 to +100 mV in about 0.05 mM KCl solution at about pH 7.5 and (e) oil-in-water emulsions or microemulsions containing cationic amphiphiles in the outer layer in the range of about 25 to 60 mol% or having a zeta potential in the range of about +25 mV to +100 mV in about 0.05 mM KC1 solution at about pH 7.5.

Claim 16 has been amended as follows:

16. (Amended) The method of claim 13 [1], wherein the composition has been modified to increase its zeta potential to a level of at least about +25 mV.

Claim 17 has been amended as follows:

17. (Amended) The method of claim 13 [1], wherein the composition has been modified through a reaction with a cation forming reagent that increases the isoelectric point of the agent relative to the non-modified agent to a value above 7.5.